Sirona Biochem (Seite 2346)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 30.04.24 15:18:17 von
neuester Beitrag 30.04.24 15:18:17 von
Beiträge: 31.028
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 26
Gesamt: 5.402.040
Gesamt: 5.402.040
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0435
EUR
+3,57 %
+0,0015 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
08.04.24 · globenewswire  |
05.04.24 · globenewswire |
28.03.24 · globenewswire |
13.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 0,8232 | +17,25 | |
| 3,6460 | +17,08 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Und es hat BOOM gemacht! 
News auf deutsch:
https://www.wallstreet-online.de/nachricht/11222133-sirona-b…
News auf deutsch:
https://www.wallstreet-online.de/nachricht/11222133-sirona-b…
Antwort auf Beitrag Nr.: 59.801.847 von Hydro_11 am 06.02.19 09:05:55Ein einziges Wort deutet in meinen Augen auf den Partner hin. Disruptive... Wie gestern schon von mir erwähnt,...
Endlich Kohle ohne Verwässerung. Strike jetzt gehts los
Vancouver, British Columbia – February 6, 2019 – Sirona Biochem Corp. (TSX-V: SBM) (FRANKFURT: ZSB) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market[1].
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media
[1] Fact.MR (July 2018) Retrieved from: https://globenewswire.com/news-release/2018/07/10/1535161/0/…
For more information regarding this announcement, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market[1].
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media
[1] Fact.MR (July 2018) Retrieved from: https://globenewswire.com/news-release/2018/07/10/1535161/0/…
For more information regarding this announcement, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
INFO!!!
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Vancouver, British Columbia – February 6, 2019 – Sirona Biochem Corp. (TSX-V: SBM) (FRANKFURT: ZSB) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market[1].
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Vancouver, British Columbia – February 6, 2019 – Sirona Biochem Corp. (TSX-V: SBM) (FRANKFURT: ZSB) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market[1].
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media
Trading Spotlight
Antwort auf Beitrag Nr.: 59.795.916 von SironaBiocam am 05.02.19 14:44:16Welcome back, schön dass auch du noch dabei bist;-}
Antwort auf Beitrag Nr.: 59.797.986 von techinvestor69 am 05.02.19 17:44:06Ja genau wegen solchen Spekulationen hab ich mich hier platziert. Ich hätte auch bei Rusoro alles oder nichts spielen können, aber aktuell scheint es mir hier schneller zu gehen, bis Fakten ans Licht kommen.
Antwort auf Beitrag Nr.: 59.797.725 von SironaBiocam am 05.02.19 17:19:07die Milliarde reicht für einen Lizenzdeal mit Sirona! 
Die brauchen einen neuen Blockbuster und Sirona hat ihn
Kashing!
Die brauchen einen neuen Blockbuster und Sirona hat ihn
Kashing!
Antwort auf Beitrag Nr.: 59.793.018 von xywasnun am 05.02.19 09:38:15auch interessant für den Akne-Wirkstoff von Sirona!
Dermatologists Katie Rodan and Kathy Fields first made a fortune with acne products endorsed by celebrities like Justin Bieber.
...
"They’ve been very successful," said Susie Qu, an analyst at S&P. "As they get larger, it will be more difficult to deliver double-digit growth."
The company is now seeking financing weeks after TPG purchased a 25 percent stake for $1 billion, the people said. The debt includes a $200 million revolving credit line and a $600 million term loan, according to S&P.
...
Katie Rodan and Kathy Fields met as medical residents at Stanford University. They made their first fortune with their blockbuster acne line Proactiv, which became a sales juggernaut last decade thanks to celebrity endorsers like Jessica Simpson and Sean “Diddy” Combs.
...
The company’s $150 eyelash enhancing serum has been hashtagged more than 400,000 times on Instagram.
"It’s much easier now to have a larger network of acquaintances or connections in the digital world," said William Keep, dean of the School of Business at the College of New Jersey, who researches multilevel marketing. “This is a monetization of your network."
...
The odds of runaway success may be slim for an individual seller, but the company can still do well: it generates about $1.7 billion in revenue a year, according to Moody’s Investors Service.
...
Quelle: https://www.bloomberg.com/news/articles/2018-06-07/two-derma…
Dermatologists Katie Rodan and Kathy Fields first made a fortune with acne products endorsed by celebrities like Justin Bieber.
...
"They’ve been very successful," said Susie Qu, an analyst at S&P. "As they get larger, it will be more difficult to deliver double-digit growth."
The company is now seeking financing weeks after TPG purchased a 25 percent stake for $1 billion, the people said. The debt includes a $200 million revolving credit line and a $600 million term loan, according to S&P.
...
Katie Rodan and Kathy Fields met as medical residents at Stanford University. They made their first fortune with their blockbuster acne line Proactiv, which became a sales juggernaut last decade thanks to celebrity endorsers like Jessica Simpson and Sean “Diddy” Combs.
...
The company’s $150 eyelash enhancing serum has been hashtagged more than 400,000 times on Instagram.
"It’s much easier now to have a larger network of acquaintances or connections in the digital world," said William Keep, dean of the School of Business at the College of New Jersey, who researches multilevel marketing. “This is a monetization of your network."
...
The odds of runaway success may be slim for an individual seller, but the company can still do well: it generates about $1.7 billion in revenue a year, according to Moody’s Investors Service.
...
Quelle: https://www.bloomberg.com/news/articles/2018-06-07/two-derma…
Antwort auf Beitrag Nr.: 59.797.650 von techinvestor69 am 05.02.19 17:13:08Mary Kay Ash ist übrigens auch schon ewig tot... um das Bild abzurunden
Durchsuchen
